Cholestyramine Pellets with Dual Coating for Colon Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cholestyramine treatments for bile acid malabsorption are limited by high doses, gastrointestinal side effects, interactions with other drugs, and malabsorption of fats and fat-soluble vitamins, necessitating a formulation that targets delivery to the colon for reduced dosage and improved tolerance.
Innovation Solution
Development of small, stable cholestyramine pellets coated with a diffusion-controlled inner coating and an enteric outer coating, ensuring more than 70% of cholestyramine is released in the colon, minimizing release in the small intestine and reducing interactions with other gastrointestinal components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of cholestyramine are administered to treat bile acid malabsorption, then the binding of bile acids is improved, but gastrointestinal side effects and drug interactions increase
Solution Approach 1:
The patent applies local quality by using a dual-coating system where the inner coating provides diffusion control and the outer enteric coating provides pH-dependent release protection. This allows the cholestyramine to remain inactive in the stomach and small intestine (avoiding side effects) and only become active in the colon (where it binds bile acids), thus improving therapeutic reliability while reducing harmful gastrointestinal effects.
2Reliability
If cholestyramine is administered orally, then bile acid binding is achieved, but interactions with other drugs and malabsorption of fats occur
Solution Approach 1:
The patent applies preliminary action by pre-coating the cholestyramine pellets with diffusion-controlled inner coating and enteric outer coating before administration. This preliminary protective action ensures that the cholestyramine remains inactive during passage through the stomach and small intestine, preventing drug interactions and fat malabsorption, and only becomes active when it reaches the colon where it is needed for bile acid binding.
3Loss of time
If cholestyramine is released in the small intestine, then bile acid binding occurs early, but side effects and drug interactions are minimized
Solution Approach 1:
The patent uses local quality through spatially differentiated coating properties: the inner diffusion-controlled coating allows gradual water penetration and swelling, while the outer enteric coating provides pH-dependent protection. This creates localized functional zones that control the timing and location of cholestyramine activation, ensuring it remains inactive in the small intestine (avoiding side effects) and only becomes active in the colon.
4Reliability
If cholestyramine pellets are coated with diffusion-controlled inner coating and enteric outer coating, then targeted delivery to colon is achieved, but formulation complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the coating system into two distinct functional layers: an inner diffusion-controlled coating and an outer enteric coating. This segmentation allows each layer to perform its specific function independently (diffusion control and pH-dependent protection), achieving reliable targeted delivery to the colon while maintaining a manageable formulation structure through modular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This formulation allows for a lower effective dose of cholestyramine, reducing gastrointestinal side effects and drug interactions, while effectively binding bile acids in the colon, thereby alleviating bile acid malabsorption and diarrhea.
Implementation Method 1
coated with a diffusion-controlled inner coating and an enteric outer coating
Implementation Method 2
an enteric outer coating, wherein more than 70% of the cholestyramine is released in the colon
Implementation Method 3
Cholestyramine is a strongly basic anion-exchange resin that is practically insoluble in water and is not absorbed from the gastrointestinal tract. Instead, it absorbs and combines with the bile acids in the intestine to form an insoluble complex
Data Source
AI summary
The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a diffusion-controlled inner coating and an enteric outer coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.